Clozapine is the primary antipsychotic (APD) for treatment-resistant schizophrenia (TRS). However, only 40% of patients with TRS respond to clozapine, constituting a subgroup of clozapine-resistant patients. Recently, the neuropeptide orexin-A was shown to be involved in the pathophysiology of schizophrenia. This study evaluated the association of orexin-A levels with the clozapine response in patients with TRS.
Methods:
We recruited 199 patients with schizophrenia, including 37 APD-free and 162 clozapine-treated patients. Clozapine-treated patients were divided into clozapine-responsive (n = 100) and clozapine-resistant (n = 62) groups based on whether they had achieved psychotic remission defined by the 18-item Brief Psychiatric Rating Scale (BPRS-18). We compared blood orexin-A levels among the three groups and performed regression analysis to determine the association of orexin-A level with treatment response in clozapine-treated patients. We also explored the correlation between orexin-A levels and cognitive function, assessed using the CogState Schizophrenia Battery.
Results:
Clozapine-responsive patients had higher orexin-A levels than clozapine-resistant and APD-free patients. Orexin-A level was the only factor significantly associated with treatment response after adjustment. Orexin-A levels were negatively correlated with BPRS-18 full scale and positive, negative, and general symptoms subscale scores. We also observed a positive correlation between orexin-A levels and verbal memory, visual learning and memory, and working memory function.
Conclusions:
This cross-sectional study showed that higher levels of orexin-A are associated with treatment response to clozapine in patients with TRS. Future prospective studies examining changes in orexin-A level following clozapine treatment and the potential benefit of augmenting orexin-A signaling are warranted.
AhleniusS (1999) Clozapine: Dopamine D1 receptor agonism in the prefrontal cortex as the code to decipher a Rosetta stone of antipsychotic drugs. Pharmacol Toxicol84: 193–196.
2.
AndreasenNCCarpenterWTJr.KaneJM, et al (2005) Remission in schizophrenia: Proposed criteria and rationale for consensus. Am J Psychiatry162: 441–449.
3.
AracriPBanfiDPasiniME, et al (2015) Hypocretin (orexin) regulates glutamate input to fast-spiking interneurons in layer V of the Fr2 region of the murine prefrontal cortex. Cereb Cortex25: 1330–1347.
4.
BaiYMLinCCChenJY, et al (2006) Association of initial antipsychotic response to clozapine and long-term weight gain. Am J Psychiatry163: 1276–1279.
5.
BorglandSLTahaSASartiF, et al (2006) Orexin A in the VTA is critical for the induction of synaptic plasticity and behavioral sensitization to cocaine. Neuron49: 589–601.
6.
BuckleyPMillerAOlsenJ, et al (2001) When symptoms persist: Clozapine augmentation strategies. Schizophr Bull27: 615–628.
7.
CalvaCBFayyazHFadelJR (2018) Increased acetylcholine and glutamate efflux in the prefrontal cortex following intranasal orexin-A (hypocretin-1). J Neurochem145: 232–244.
8.
ChanSKWChanHYVHonerWG, et al (2020) Predictors of treatment-resistant and clozapine-resistant schizophrenia: A 12-year follow-up study of first-episode schizophrenia-spectrum disorders. Schizophr Bull47: 485–494.
9.
ChenPYChangCKChenCH, et al (2022) Orexin-a elevation in antipsychotic-treated compared to drug-free patients with schizophrenia: A medication effect independent of metabolic syndrome. J Formos Med Assoc121: 2172–2181.
10.
ChenPYChenCHChangCK, et al (2019) Orexin-A levels in relation to the risk of metabolic syndrome in patients with schizophrenia taking antipsychotics. Int J Neuropsychopharmacol22: 28–36.
11.
ChenXYChenLDuYF (2017) Orexin-A increases the firing activity of hippocampal CA1 neurons through orexin-1 receptors. J Neurosci Res95: 1415–1426.
12.
ChienYLLiuCMShanJC, et al (2015) Elevated plasma orexin A levels in a subgroup of patients with schizophrenia associated with fewer negative and disorganized symptoms. Psychoneuroendocrinology53: 1–9.
13.
ChiuYHHsuCYLuML, et al (2020) Augmentation strategies for clozapine-resistant patients with schizophrenia. Curr Pharm Des26: 218–227.
14.
CorrellCUSchoolerNR (2020) Negative symptoms in schizophrenia: A review and clinical guide for recognition, assessment, and treatment. Neuropsychiatr Dis Treat16: 519–534.
15.
de LeonJRajkumarAPKaithiAR, et al (2020) Do Asian patients require only half of the clozapine dose prescribed for caucasians? A critical overview. Indian J Psychol Med42: 4–10.
16.
DeutchAYBubserM (2007) The orexins/hypocretins and schizophrenia. Schizophr Bull33: 1277–1283.
17.
FadelJBubserMDeutchAY (2002) Differential activation of orexin neurons by antipsychotic drugs associated with weight gain. J Neurosci22: 6742–6746.
18.
GillespieALSamanaiteRMillJ, et al (2017) Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? a systematic review. BMC Psychiatry17: 12–12.
19.
GoldsteinMEAndersonVMPillaiA, et al (2015) Glutamatergic neurometabolites in clozapine-responsive and -resistant schizophrenia. Int J Neuropsychopharmacol18: pyu117.
20.
Gonzalez-BurgosGChoRYLewisDA (2015) Alterations in cortical network oscillations and parvalbumin neurons in schizophrenia. Biol Psychiatry77: 1031–1040.
21.
GraceAAGomesFV (2019) The circuitry of dopamine system regulation and its disruption in schizophrenia: Insights into treatment and prevention. Schizophr Bull45: 148–157.
22.
GriffithsKMillgateEEgertonA, et al (2021) Demographic and clinical variables associated with response to clozapine in schizophrenia: A systematic review and meta-analysis. Psychol Med51: 376–386.
23.
GrundySMCleemanJIDanielsSR, et al (2005) Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation112: 2735–2752.
24.
HaddadPMCorrellCU (2018) The acute efficacy of antipsychotics in schizophrenia: A review of recent meta-analyses. Ther Adv Psychopharmacol8: 303–318.
25.
HowesODMcCutcheonRAgidO, et al (2017) Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry174: 216–229.
26.
HuntNJRodriguezMLWatersKA, et al (2015) Changes in orexin (hypocretin) neuronal expression with normal aging in the human hypothalamus. Neurobiol Aging36: 292–300.
27.
JiMJZhangXYChenZ, et al (2019) Orexin prevents depressive-like behavior by promoting stress resilience. Mol Psychiatry24: 282–293.
28.
KaneJHonigfeldGSingerJ, et al (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry45: 789–796.
29.
KasterTSde JesusDRadhuN, et al (2015) Clozapine potentiation of GABA mediated cortical inhibition in treatment resistant schizophrenia. Schizophr Res165: 157–162.
30.
LeeWCChenPYKaoCF, et al (2020) Differences in serum orexin-A levels between the acute and subacute withdrawal phases in individuals who use methamphetamine. Exp Clin Psychopharmacol29: 573.
31.
LinehanVRoweTMHirasawaM (2019) Dopamine modulates excitatory transmission to orexin neurons in a receptor subtype-specific manner. Am J Physiol Regul Integr Comp Physiol316: R68–R75.
32.
LuJHuangM-LLiJ-H, et al (2021) Changes of hypocretin (orexin) system in schizophrenia: From plasma to brain. Schizophrenia Bulletin47: 1310–1319.
33.
MavanjiVButterickTADuffyCM, et al (2017) Orexin/hypocretin treatment restores hippocampal-dependent memory in orexin-deficient mice. Neurobiol Learn Mem146: 21–30.
34.
NakazawaKJeevakumarVNakaoK (2017) Spatial and temporal boundaries of NMDA receptor hypofunction leading to schizophrenia. NPJ Schizophrenia3: 7.
35.
NocjarCZhangJFengP, et al (2012) The social defeat animal model of depression shows diminished levels of orexin in mesocortical regions of the dopamine system, and of dynorphin and orexin in the hypothalamus. Neuroscience218: 138–153.
36.
PietrzakRHOlverJNormanT, et al (2009) A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia. J Clin Exp Neuropsychol31: 848–859.
37.
RajkumarAPChitraCBhuvaneshwariS, et al (2011) Clinical predictors of response to clozapine in patients with treatment resistant schizophrenia. Psychopharmacol Bull44: 51–65.
38.
RodríguezBNaniJVAlmeidaPGC, et al (2020) Neuropeptides and oligopeptidases in schizophrenia. Neurosci Biobehav Rev108: 679–693.
39.
RosslerWSalizeHJvan OsJ, et al (2005) Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol15: 399–409.
40.
SakuraiTAmemiyaAIshiiM, et al (1998) Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell92: 573–585.
41.
SamanaiteRGillespieASendtK-V, et al (2018) Biological predictors of clozapine response: A systematic review. Front Psychiatry9: 327.
42.
SanguesaECirujedaCConchaJ, et al (2022) Exploring the usefulness of plasma level determination and pharmacogenetics for patients treated with clozapine. Per Med19: 181–192.
43.
SelbachODoreuleeNBohlaC, et al (2004) Orexins/hypocretins cause sharp wave- and theta-related synaptic plasticity in the hippocampus via glutamatergic, gabaergic, noradrenergic, and cholinergic signaling. Neuroscience127: 519–528.
44.
SheehanDVLecrubierYSheehanKH, et al (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry59: 22–33.
45.
ShimizuSTakenoshitaNInagawaY, et al (2020) Positive association between cognitive function and cerebrospinal fluid orexin a levels in Alzheimer’s Disease. J Alzheimers Dis73: 117–123.
46.
SiskindDSiskindVKiselyS (2017) Clozapine response rates among people with treatment-resistant schizophrenia: Data from a systematic review and meta-analysis. Can J Psychiatry62: 772–777.
47.
StewardTMestre-BachGGraneroR, et al (2019) Reduced plasma orexin-A concentrations are associated with cognitive deficits in anorexia nervosa. Sci Rep9: 7910.
48.
StrawnJRPyne-GeithmanGJEkhatorNN, et al (2010) Low cerebrospinal fluid and plasma orexin-A (hypocretin-1) concentrations in combat-related posttraumatic stress disorder. Psychoneuroendocrinology35: 1001–1007.
49.
UsuiMKanekoKOiY, et al (2019) Orexin facilitates GABAergic IPSCs via postsynaptic OX1 receptors coupling to the intracellular PKC signalling cascade in the rat cerebral cortex. Neuropharmacology149: 97–112.
50.
VassalliAFrankenP (2017) Hypocretin (orexin) is critical in sustaining theta/gamma-rich waking behaviors that drive sleep need. Proc Natl Acad Sci USA114: E5464–E5473.
51.
VeermanSRTSchultePFJSmithJD, et al (2016) Memantine augmentation in clozapine-refractory schizophrenia: A randomized, double-blind, placebo-controlled crossover study. Psychol Med46: 1909–1921.
52.
VittozNMBerridgeCW (2006) Hypocretin/orexin selectively increases dopamine efflux within the prefrontal cortex: Involvement of the ventral tegmental area. Neuropsychopharmacology31: 384–395.
WagnerEKaneJMCorrellCU, et al (2020) Clozapine combination and augmentation strategies in patients with schizophrenia -recommendations from an international expert survey among the Treatment Response and Resistance in Psychosis (TRRIP) working group. Schizophr Bull46: 1459–1470.
55.
WaynerMJArmstrongDLPhelixCF, et al (2004) Orexin-A (Hypocretin-1) and leptin enhance LTP in the dentate gyrus of rats in vivo. Peptides25: 991–996.
56.
WuMZhangZLeranthC, et al (2002) Hypocretin increases impulse flow in the septohippocampal GABAergic pathway: Implications for arousal via a mechanism of hippocampal disinhibition. J Neurosci22: 7754–7765.
57.
YamanakaAMurakiYIchikiK, et al (2006) Orexin neurons are directly and indirectly regulated by catecholamines in a complex manner. J Neurophysiol96: 284–298.
58.
YangLZouBXiongX, et al (2013) Hypocretin/orexin neurons contribute to hippocampus-dependent social memory and synaptic plasticity in mice. J Neurosci33: 5275–5284.
59.
ZhaoXZhangRTangS, et al (2014) Orexin-A-induced ERK1/2 activation reverses impaired spatial learning and memory in pentylenetetrazol-kindled rats via OX1R-mediated hippocampal neurogenesis. Peptides54: 140–147.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
